139 related articles for article (PubMed ID: 20520552)
1. How early should psoriatic arthritis be treated with a TNF-blocker?
Harty L; Veale DJ
Curr Opin Rheumatol; 2010 Jul; 22(4):393-6. PubMed ID: 20520552
[TBL] [Abstract][Full Text] [Related]
2. Improving recognition of psoriatic arthritis.
Conaghan PG; Coates LC
Practitioner; 2009 Dec; 253(1724):15-8, 2-3. PubMed ID: 20120827
[TBL] [Abstract][Full Text] [Related]
3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
4. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
Haibel H; Sieper J
Curr Opin Rheumatol; 2010 Jul; 22(4):388-92. PubMed ID: 20473176
[TBL] [Abstract][Full Text] [Related]
5. TNF inhibitors in the treatment of arthritis.
Lorenz HM
Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
[TBL] [Abstract][Full Text] [Related]
6. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
[TBL] [Abstract][Full Text] [Related]
7. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
8. Current concepts and new developments in the treatment of psoriatic arthritis.
Pipitone N; Kingsley GH; Manzo A; Scott DL; Pitzalis C
Rheumatology (Oxford); 2003 Oct; 42(10):1138-48. PubMed ID: 12810935
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
10. Resistant cases of psoriatic arthritis: how to manage them.
Atzeni F; Sarzi-Puttini P; Vena GA
J Rheumatol Suppl; 2009 Aug; 83():73-5. PubMed ID: 19661549
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
Pomerantz RG; Mody E; Husni ME; Qureshi AA
J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary focus on methotrexate in psoriatic disesase.
Marchesoni A; Ricci M; Moggio E; Brazzelli V; Borroni G
J Rheumatol Suppl; 2009 Aug; 83():56-8. PubMed ID: 19661543
[TBL] [Abstract][Full Text] [Related]
13. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis.
Soriano ER
J Rheumatol Suppl; 2012 Jul; 89():67-70. PubMed ID: 22751597
[TBL] [Abstract][Full Text] [Related]
14. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
15. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs.
Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
J Rheumatol Suppl; 2009 Aug; 83():78-80. PubMed ID: 19661551
[TBL] [Abstract][Full Text] [Related]
16. Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs.
Lubrano E; Scarpa R
Reumatismo; 2012 Jun; 64(2):107-12. PubMed ID: 22690387
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
18. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
19. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
20. Psoriatic arthritis.
Wollina U; Unger L; Heinig B; Kittner T
Dermatol Ther; 2010; 23(2):123-36. PubMed ID: 20415819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
